Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03187015 · ClinicalTrials.gov registry record · Phase 1

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

A Phase 1 study of Healthy Volunteer and Drug Interaction, sponsored by Syndax Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT03187015: Completed Phase 1 study of Healthy Volunteer and Drug Interaction, sponsored by Syndax Pharmaceuticals.

NCT03187015 is a Phase 1 study of Healthy Volunteer and Drug Interaction that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 26 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03187015, a Phase 1 study of Healthy Volunteer and Drug Interaction, has completed, sponsored by Syndax Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of Entinostat on the bioavailability of Midazolam. The primary objective is to evaluate the effect of a single oral dose of entinostat on the pharmacokinetics (PK) of a single oral dose of midazolam in healthy subjects. The secondary objective is to evaluate the safety and tolerability of combined administration of entinostat and midazolam in healthy subjects.

Primary Outcome

AUC0-t for midazolam and 1 OH midazolam will be computed.

Interventions

  • DRUG Midazolam
  • DRUG Entinostat

Study Locations (1)

Nebraska

  • Celerion - Lincoln

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2017-05-23
Est. Completion 2017-08-22
Phase Phase 1
Syndax Pharmaceuticals

25 total trials

What the finished NCT03187015 record still lists

NCT03187015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT03187015 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT03187015 about?

NCT03187015 is a clinical study titled "A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects". The purpose of this study is to evaluate the effect of Entinostat on the bioavailability of Midazolam. The primary objective is to evaluate the effect of a single oral dose of entinostat on the pharmacokinetics (PK) of a single oral dose of midazolam in healthy subjects. The secondary objective is...

What is the current status of trial NCT03187015?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-05-23. Estimated completion is 2017-08-22.

What conditions does trial NCT03187015 study?

This clinical trial studies the following conditions: Healthy Volunteer, Drug Interaction.

What interventions are being tested in trial NCT03187015?

The interventions under investigation include: Midazolam (DRUG), Entinostat (DRUG).

Who is sponsoring clinical trial NCT03187015?

This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03187015 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03187015's enrollment target sits among peer trials

26 83rd of 112 higher than 30 of 112 other Healthy Volunteer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03187015, the US trial registry maintained by the National Library of Medicine. NCT03187015 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.